Hematopoietic stem cell transplantation for acute myeloid leukemia.

The standard treatment for de novo acute myeloid leukemia (AML) has been established. Although patients with AML achieve complete remission at high rates, the long-term prognosis for such patients remains unsatisfactory. It is therefore necessary to perform hematopoietic stem cell transplantation (HSCT) to improve their outcomes. However, a high rate of transplant-related mortality continues to be a problem associated with allogeneic HSCT. We therefore need to carefully determine the indications for safely performing HSCT based on historical data.